VILYA
AI-powered platform for designing novel molecular structures for new medicines.
About
Vilya pioneers computational drug design, creating entirely new de novo macrocycles inspired by biology and designed using AI. Their platform generates, predicts, and validates these molecules in silico, aiming to develop orally bioavailable therapies that combine the selectivity of biologics with the convenience of pills. Vilya serves the pharmaceutical and biotechnology industries by advancing a new class of medicines for previously untreatable diseases. Teams look it up for BIO + LIFE SCIENCES, Biotech, Drug Discovery.
Frequently asked
What does VILYA do?
VILYA is a BIO + LIFE SCIENCES company that offers Platform. Teams look it up for Biotech, Drug Discovery, Genomics. It is based in San Francisco, United States and was founded in 2022. Public records show about 47 people and $121M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has VILYA raised?
VILYA has raised a total of $121M in funding. The most recent round on record is Series A.
Where is VILYA headquartered?
VILYA is headquartered in San Francisco, United States.
When was VILYA founded?
VILYA was founded in 2022.
What industry does VILYA operate in?
VILYA operates in BIO + LIFE SCIENCES, Biotech, Drug Discovery, Genomics, AI-Driven Protein Design.
How many employees does VILYA have?
VILYA has approximately 47 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.